Chronic heart failure (CHF) is characterized by a limitation in exercise capacity caused by breathlessness and fatigue. There is substantial evidence to suggest that these symptoms are largely determined by abnormalities of peripheral blood flow and skeletal muscle function, as opposed to central haemodynamic disturbances. Muscle atrophy and loss of strength, decreased oxidative capacity and structural changes in the skeletal musculatm-e have all been reported in CHF. Abnormalities in peripheral blood flow also predict reduced exercise capacity, particularly in patients with cardiac cachexia. Endothelial dysfunction is present in CHF, together with an increase in peripheral vasomotor tone. The factors that regulate endothelial function in CHF are complex and poorly understood. The present review addresses abnormalities in endothelial function, regional blood flow and skeletal muscle in CHF, and their contributions to tissue wasting and cachexia. 
Introduction
The principal symptoms of chronic heart failure (CHF) are dyspnoea and fatigue, which contribute to the high morbidity and poor quality of life associated with this condition. Symptoms in CHF relate poorly to central haemodynamic indices, being more closely linked to changes in skeletal muscle morphology and physiology [1] . Many patients with CHF develop a wasting syndrome, termed 'cardiac cachexia', which until recently has been little investigated[2l.
Patients with advanced CHF, particularly those who are cachectic, have abnormalities in peripheral blood flow, which have been shown to be significant predictors of exercise capacity [31. In CHF there is an impaired response to vasodilatory stimuli (endothelial dysfunction), together with an increase in peripheral vasomotor tone [4-6? . The factors that regulate endothelial function in heart failure are complex and at present incompletely understood. The present review addresses the abnormalities of endothelial 
Endothelial dysfunction
The phenomenon of endothelial dysfimction in CHF was first described by Forstermann et al.tT] . These investigators demonstrated a diminished vasodilatory response to acetylcholine in epicardial coronary arteries that had been isolated from the explanted hearts of patients with idiopathic and ischaemic cardiomyopathies. Vascular endothelial cell dysfunction has since also been shown to occur in skeletal muscle in CHF, and is therefore probably an important determinant of skeletal muscle blood flow and exercise capacity. Endothelial dysfunction can result in impaired tissue perfusion (particularly during stress) and myocardial ischaemia, and may also have adverse long-term effects on vascular remodelling [8] .
Shear stress is proposed to play an important role in the development of endothelial dysfunction in CHF. Under normal conditions shear stress stimulates the release of log TNF (pg. ml -~) Figure 1 Relationship between peak leg blood flow and tumour necrosis factor (TNF) in 34 chronic heart failure patients. (Adapted from Anker et ai.[22l.) vasodilators such as nitric oxide and prostacyclin, and inhibition of vasoconstrictors such as endothelin (ET)-I. Shear stress is reduced in low-output states such as CHF, which may partly explain the impairment in vasodilatory capacity that is observed in this condition [9] . Other factors that are implicated in the development of endothelial dysfunction include increased oxidative stress, neurohormonal and cytokine activation, and alterations in regional blood flow [S°] .
Oxidative stress and nitric oxide
Oxygen free radicals are increased in CHF, and are believed to be involved in the processes of cardiac remodelling and apoptosis. Thus, they may be important determinants of exercise capacity in heart failure[U,121. Serum uric acid is a marker of oxidative stress and increased xanthine oxidase, and is significantly elevated in CHF [ 13] . This elevation is independent of renal function and the degree of diuretic treatment [~4] . Studies have shown a strong inverse relationship between serum uric acid concentration and maximum leg blood flow in patients with CHF[151. In addition, it has recently been reported that serum uric acid is an independent predictor of peripheral vascular resistance in CHF, particularly in cachectic patients [16] . Moreover, there is evidence that allopurinol, a xanthine oxidase inhibitor, reduces endothelial dysfunction in patients with CHF, possibly by reducing free radical formation [17, 18] . Allopurinol may therefore represent a cost-effective therapy for reducing oxidative stress in heart failure.
Nitric oxide is also an important focus of research, and may play a role in the poorly understood molecular mechanisms that underlie exercise intolerance in CHE It has been proposed that nitric oxide is a key regulator in pulmonary vasodilatation during exercise. Abnormalities of regional blood flow in the pulmonary vasculature could explain why CHF patients exhibit an increased ventilatory response to exercise. Compared with healthy control individuals, CHF patients also have a smaller increase in nitric oxide production during exercise. This reduced nitric oxide production might be responsible for reduced pulmonary vasodilatation, leading to an abnormally high respiratory rate and thus to dyspnoea[19j.
Abnormalities in nitric oxide production in the skeletal muscle may also contribute to exercise intolerance in CHF. Expression of inducible nitric oxide synthase (iNOS; the enzyme that is responsible for the synthesis of nitric oxide from L-arginine) is increased in the skeletal muscle of patients with CHF. Expression of iNOS correlates inversely with expression of mitochondrial creatine kinase (a key enzyme for rapid energy transfer from mitochondria to the cytosol) and with exercise capacity [20] .
Apoptosis
Oxidative stress and iNOS expression are also linked to apoptosis (programmed cell death). Apoptosis occurs not only in the myocardium but also in the skeletal muscle of patients with CHF. Apoptosis is present in approximately 50% of skeletal muscle biopsies from patients with CHF, and is associated with a lower exercise capacity [21] , iNOS expression is increased and the expression of Bcl-2 (an antiapoptotic oncogene) is reduced in patients with apoptosis-positive myocytes, suggesting that iNOS and Bcl-2 play regulatory roles in apoptosis. Furthermore, tumour necrosis factor (TNF)-alpha, which can stimulate the production of iNOS, has a strong inverse relationship with peak leg blood flow in patients with CHF ( Fig. 1) [221. The effects of TNF on iNOS, and thereby on skeletal muscle apoptosis, could explain the inverse relationship between high levels of inflammatory cytokines such as TNF and exercise capacity in CHF [23] .
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Endothelin-1
Another important mediator that plays a crucial role in the regulation of endothelial function is ET-I [ 24] , Endothelins belong to a group of peptides that are released from endothelial cells and have potent vasoconstrictor activities. .=. The main member of the family is ET-1, which is synthesized from its precursor big ET-1 via an endothelinconverting enzyme.
The [26] . In vitro studies have shown that ET-1 can stimulate the production of TNF and thus contribute to the inflammatory cytokine activation seen in CHF[271. It has been reported that high ET-1 levels are associated with increased severity of CHF and higher mortality [28] . Furthermore, high ET-1 levels are associated with exercise-E induced brachial artery constriction in patients with CHF[29~.
.~ The main source of circulating ET-1 in patients with CHF o is the pulmonary vascular bed, and studies suggest that ET-1 is involved in regulating pulmonary vascular resistance[301.
-~ Pulmonary hypertension is known to be an important indicator of prognosis in CHF, and its severity is reduced by therapy with endothelin receptor antagonists [31] . Preliminary g studies with such agents in CHF have demonstrated an "~ improvement in left ventricular performance, together with _~ reductions in mean arterial pressure, mean pulmonary artery capillary wedge pressure and systemic vascular resistance[321. However, further studies are needed to determine whether endothelin receptor antagonists have benefits on symptoms or prognosis in CHF [33] .
Cardiac cachexia
A significant number of patients with advanced heart failure develop cardiac cachexia, a generalized wasting syndrome that is associated with an extremely poor prognosis [34] In CHF patients with cardiac cachexia, skeletal muscle blood flow is an important predictor of exercise capacity, whereas in patients without wasting it is not (Fig. 2) [31. Furthermore, there is a positive correlation between impairment in endothelium-dependent vasodilatation in forearm conduit vessels and serum TNF levels in CHF, which suggests that cytokines may play a significant role in the regulation of peripheral blood flow in this condition[411.
Skeletal muscle atrophy
Several disturbances in skeletal muscle physiology have been observed in CHF at both the molecular and functional levels. Research into the cause of these abnormalities is clinically important, particularly in view of the favourable results of exercise training in heart failure [42] . Patients with CHF characteristically have evidence of muscle atrophy [43, 44] , which may be present in up to two-thirds of patients [4S] . When CHF patients are divided into groups according to the presence or absence of documented weight loss, cachectic patients show not only significant loss of lean tissue but also gross reduction in fat tissue mass (i.e. energy reserves) and evidence of decreased bone mineral density (i.e. osteoporosis) [3] . Studies using dual-energy X-ray absorptiometry [ 46, 47] have confirmed that cachectic CHF patients have a reduction in total body fat, lean tissue mass and bone mineral density [48] as compared with non-cachectic persons and healthy control individuals.
Considering the loss of muscle tissue (muscle quantity), it is not surprising that cachectic CHF patients show greater muscle weakness than non-cachectic patients (39% lower strength in both legs). However, they also show a 16% reduction in strength per unit muscle (i.e. impaired muscle quality)[3J. The loss of muscle tissue is important; together with impaired peripheral blood flowE49], it contributes to the decreased oxidative capacity that is the primary cause of impaired exercise capacity in CHF patients.
Growth hormone abnormalities and apoptosis
Alterations in the growth hormone/insulin-like growth factor (IGF)-I axis have been demonstrated in CHF, and may play an important role in the pathogenesis of the wasting process. Levels of growth hormone are elevated in cachectic CHF patients, together with inappropriately normal or low levels of IGF-I, suggesting the presence of growth hormone resistance [50] . Patients with low IGF-I levels have more severe abnormalities in body composition, neuroendocrine and cytokine activation than do patients with normal/high levels [ As noted above, apoptosis occurs in the skeletal muscle of patients with CHF and is associated with a significant impairment in exercise capacity [21] . Although it is likely that apoptosis is particularly frequent in cardiac cachexia, this has not yet been studied.
Conclusion
It is apparent that CHF is a clinical syndrome in which there are complex interactions between different body systems (Fig. 3) [541. There is increasing evidence that the abnormalities in peripheral blood flow and skeletal muscle function that occur in CHF are responsible for symptom generation in this condition. Furthermore, it may be hypothesized that drugs such as angiotensin-converting enzyme inhibitors may exert their beneficial effects on CHF via their influence on endothelial and peripheral muscle function, rather than their central haemodynamic effects. It is hoped that improvement in our understanding of the pathophysiological changes that occur in heart failure will lead to development of novel strategies for the treatment of this debilitating condition. R.S. is supported by the Robert Luff Foundation. S.D.A. is supported by a postgraduate fellowship of the Max Delbriick Centrum for Molecular Medicine, Berlin, Germany.
